Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Viracta (Details)

v3.22.2.2
Royalty and Commercial Payment Purchase Agreements - Viracta (Details)
$ in Thousands
9 Months Ended 12 Months Ended
Mar. 22, 2021
USD ($)
item
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Agreements        
Payments related to purchase of royalty rights and other commercial payment rights     $ 20,500  
Long-term royalty and commercial payment receivables   $ 66,049   $ 69,075
Impairment of long-term royalty receivable   0   0
Viracta | Royalty Purchase Agreement        
Agreements        
Number of drug candidates | item 2      
Payments related to purchase of royalty rights and other commercial payment rights $ 13,500      
Maximum amount of potential milestones and other payments receivable 54,000      
Amount of maximum consideration retained 20,000      
Maximum amount of potential regulatory and commercial milestones receivable 57,000      
Long-term royalty and commercial payment receivables $ 13,500      
Impairment of long-term royalty receivable   $ 0   $ 0